Jimenez R

No ORCID on file · 5 papers in corpus · active 2002-2014

Study types

  • article 4
  • other 1

Condition tags

  • endometriosis 5
  • chronic_pelvic_pain 2
  • dysmenorrhea 1
  • dyspareunia 1
  • bladder_endometriosis 1
article 2014
Elagolix, an Oral GnRH Antagonist, Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis: Effects on Bone Mineral Density
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1177/1933719114549848

This randomized double-blind study, with 24-week treatment and 24-week posttreatment periods, evaluated the effects of elagolix (150 mg every day, 75 mg twice a day) versus subcutaneous depot medroxyprogesterone acetate (DMPA-SC) on bone mi…

article 2013
Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study
Journal of endometriosis and pelvic pain disorders ·doi:10.5301/je.5000157

OBJECTIVE: The aim of this study was to estimate the efficacy of elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of endometriosis-associated pelvic pain. METHODS: This was a phase II, randomized, placeb…

article 2013
Elagolix Treatment for Endometriosis-Associated Pain: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1177/1933719113497292

This Phase 2 study evaluated the safety and efficacy of elagolix for treating endometriosis-associated pain. A total of 155 women with laparoscopically confirmed endometriosis were randomized to placebo, elagolix 150 mg, or elagolix 250 mg …

article 2008
Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide Gonadotropin-Releasing Hormone Antagonist Elagolix
The Journal of clinical endocrinology and metabolism ·doi:10.1210/jc.2008-1695

CONTEXT: Parenteral administration of peptide GnRH analogs is widely employed for treatment of endometriosis and fibroids and in assisted-reproductive therapy protocols. Elagolix is a novel, orally available nonpeptide GnRH antagonist. OBJE…

other 2002
Clear cell carcinoma of the urinary bladder: a report and comparison of four tumors of mullerian origin and nine of probable urothelial origin with discussion of histogenesis and diagnostic problems
The American journal of surgical pathology ·doi:10.1097/00000478-200202000-00005

Carcinomas of the bladder that resemble clear cell carcinoma of mullerian type are rare. Whether such neoplasms 1) arise from mullerian elements in the bladder and are histogenetically identical to the female genital tract cancer, 2) are a …